Clinical trial · Interventional
Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors
A Phase I Study of Cetuximab in Combination With Erlotinib in Patients With Advanced Solid Malignancies
NCT00207077CI-TRIAL-00019638completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to find a safe and effective dose of the combination of cetuximab (Erbitux) and Tarceva (erlotinib).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms | Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cetuximab + Erlotinib | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- A
- interventionNames
- Drug: Cetuximab + Erlotinib
Primary outcomes (1)
- measure
- Safety and efficacy of the combination of Tarceva and Erbitux
Secondary outcomes (1)
- measure
- Radiographic response
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Measurable disease * Life expectancy of at least 3 months * Must have at least one prior chemotherapy containing a platinum Exclusion Criteria: * Known or documented brain metastases * Prior cetuximab therapy
References
Publications (0)
Data not yet available
No reference posted for this study.